The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey.


Journal

CJC open
ISSN: 2589-790X
Titre abrégé: CJC Open
Pays: United States
ID NLM: 101763635

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 30 03 2021
accepted: 12 04 2021
pubmed: 18 5 2021
medline: 18 5 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

As a result of the COVID-19 pandemic first wave, reductions in ST-elevation myocardial infarction (STEMI) invasive care, ranging from 23% to 76%, have been reported from various countries. Whether this change had any impact on coronary angiography (CA) volume or on mechanical support device use for STEMI and post-STEMI mechanical complications in Canada is unknown. We administered a Canada-wide survey to all cardiac catheterization laboratory directors, seeking the volume of CA use for STEMI performed during the period from March 1 2020 to May 31, 2020 (pandemic period), and during 2 control periods (March 1, 2019 to May 31, 2019 and March 1, 2018 to May 31, 2018). The number of left ventricular support devices used, as well as the number of ventricular septal defects and papillary muscle rupture cases diagnosed, was also recorded. We also assessed whether the number of COVID-19 cases recorded in each province was associated with STEMI-related CA volume. A total of 41 of 42 Canadian catheterization laboratories (98%) provided data. There was a modest but statistically significant 16% reduction (incidence rate ratio [IRR] 0.84; 95% confidence interval 0.80-0.87) in CA for STEMI during the first wave of the pandemic, compared to control periods. IRR was not associated with provincial COVID-19 caseload. We observed a 26% reduction (IRR 0.74; 95% confidence interval 0.61-0.89) in the use of intra-aortic balloon pump use for STEMI. Use of an Impella pump and mechanical complications from STEMI were exceedingly rare. We observed a modest 16% decrease in use of CA for STEMI during the pandemic first wave in Canada, lower than the level reported in other countries. Provincial COVID-19 caseload did not influence this reduction. Après la première vague de la pandémie de COVID-19, de nombreux pays ont déclaré une réduction de 23 % à 76 % des soins invasifs de l'infarctus du myocarde avec élévation du segment ST (STEMI). On ignore si ce changement a entraîné des répercussions sur le volume d'angiographies coronariennes (AC) ou sur l'utilisation des dispositifs d'assistance mécanique lors de STEMI et des complications mécaniques post-STEMI au Canada. Nous avons réalisé un sondage pancanadien auprès de tous les directeurs de laboratoire de cathétérisme cardiaque pour obtenir le volume d'utilisation des AC lors des STEMI réalisées durant la période du 1 Au total, 41 des 42 laboratoires canadiens de cathétérisme (98 %) ont fourni des données. Lors de la comparaison de la première vague de la pandémie aux périodes témoins, nous avons noté une réduction modeste, mais significative, sur le plan statistique de 16 % (ratio du taux d'incidence [RTI] 0,84; intervalle de confiance à 95 % 0,80-0,87) des AC lors de STEMI. Le RTI n’était pas associé au nombre provincial de cas de COVID-19. Nous avons observé une réduction de 26 % (RTI 0,74; intervalle de confiance à 95 % 0,61-0,89) de l'utilisation de pompes à ballonnet intra-aortique lors de STEMI. L'utilisation d'une pompe Impella et les complications mécaniques après les STEMI étaient extrêmement rares. Nous avons observé une diminution modeste de 16 % de l'utilisation des AC lors de STEMI durant la première vague de la pandémie au Canada, soit une diminution plus faible que ce que les autres pays ont signalé. Le nombre provincial de cas de COVID-19 n'a pas influencé cette réduction.

Sections du résumé

BACKGROUND BACKGROUND
As a result of the COVID-19 pandemic first wave, reductions in ST-elevation myocardial infarction (STEMI) invasive care, ranging from 23% to 76%, have been reported from various countries. Whether this change had any impact on coronary angiography (CA) volume or on mechanical support device use for STEMI and post-STEMI mechanical complications in Canada is unknown.
METHODS METHODS
We administered a Canada-wide survey to all cardiac catheterization laboratory directors, seeking the volume of CA use for STEMI performed during the period from March 1 2020 to May 31, 2020 (pandemic period), and during 2 control periods (March 1, 2019 to May 31, 2019 and March 1, 2018 to May 31, 2018). The number of left ventricular support devices used, as well as the number of ventricular septal defects and papillary muscle rupture cases diagnosed, was also recorded. We also assessed whether the number of COVID-19 cases recorded in each province was associated with STEMI-related CA volume.
RESULTS RESULTS
A total of 41 of 42 Canadian catheterization laboratories (98%) provided data. There was a modest but statistically significant 16% reduction (incidence rate ratio [IRR] 0.84; 95% confidence interval 0.80-0.87) in CA for STEMI during the first wave of the pandemic, compared to control periods. IRR was not associated with provincial COVID-19 caseload. We observed a 26% reduction (IRR 0.74; 95% confidence interval 0.61-0.89) in the use of intra-aortic balloon pump use for STEMI. Use of an Impella pump and mechanical complications from STEMI were exceedingly rare.
CONCLUSIONS CONCLUSIONS
We observed a modest 16% decrease in use of CA for STEMI during the pandemic first wave in Canada, lower than the level reported in other countries. Provincial COVID-19 caseload did not influence this reduction.
INTRODUCTION BACKGROUND
Après la première vague de la pandémie de COVID-19, de nombreux pays ont déclaré une réduction de 23 % à 76 % des soins invasifs de l'infarctus du myocarde avec élévation du segment ST (STEMI). On ignore si ce changement a entraîné des répercussions sur le volume d'angiographies coronariennes (AC) ou sur l'utilisation des dispositifs d'assistance mécanique lors de STEMI et des complications mécaniques post-STEMI au Canada.
MÉTHODES UNASSIGNED
Nous avons réalisé un sondage pancanadien auprès de tous les directeurs de laboratoire de cathétérisme cardiaque pour obtenir le volume d'utilisation des AC lors des STEMI réalisées durant la période du 1
RÉSULTATS UNASSIGNED
Au total, 41 des 42 laboratoires canadiens de cathétérisme (98 %) ont fourni des données. Lors de la comparaison de la première vague de la pandémie aux périodes témoins, nous avons noté une réduction modeste, mais significative, sur le plan statistique de 16 % (ratio du taux d'incidence [RTI] 0,84; intervalle de confiance à 95 % 0,80-0,87) des AC lors de STEMI. Le RTI n’était pas associé au nombre provincial de cas de COVID-19. Nous avons observé une réduction de 26 % (RTI 0,74; intervalle de confiance à 95 % 0,61-0,89) de l'utilisation de pompes à ballonnet intra-aortique lors de STEMI. L'utilisation d'une pompe Impella et les complications mécaniques après les STEMI étaient extrêmement rares.
CONCLUSIONS CONCLUSIONS
Nous avons observé une diminution modeste de 16 % de l'utilisation des AC lors de STEMI durant la première vague de la pandémie au Canada, soit une diminution plus faible que ce que les autres pays ont signalé. Le nombre provincial de cas de COVID-19 n'a pas influencé cette réduction.

Autres résumés

Type: Publisher (fre)
Après la première vague de la pandémie de COVID-19, de nombreux pays ont déclaré une réduction de 23 % à 76 % des soins invasifs de l'infarctus du myocarde avec élévation du segment ST (STEMI). On ignore si ce changement a entraîné des répercussions sur le volume d'angiographies coronariennes (AC) ou sur l'utilisation des dispositifs d'assistance mécanique lors de STEMI et des complications mécaniques post-STEMI au Canada.

Identifiants

pubmed: 33997751
doi: 10.1016/j.cjco.2021.04.017
pii: S2589-790X(21)00127-X
pmc: PMC8114614
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1125-1131

Informations de copyright

© 2021 Published by Elsevier Inc. on behalf of Canadian Cardiovascular Society.

Références

Scand Cardiovasc J. 2020 Dec;54(6):358-360
pubmed: 32945201
Rev Esp Cardiol (Engl Ed). 2020 Dec;73(12):994-1002
pubmed: 32917566
Am J Emerg Med. 2021 Jun;44:192-197
pubmed: 33039221
Lancet. 2013 Aug 17;382(9892):624-32
pubmed: 23953386
J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):869-873
pubmed: 33009170
J Am Heart Assoc. 2020 Nov 17;9(22):e018379
pubmed: 33023348
Can J Cardiol. 2020 Jul;36(7):1068-1080
pubmed: 32425328
Public Health. 2020 Oct;187:115-119
pubmed: 32949881
JACC Case Rep. 2020 Aug;2(10):1603-1609
pubmed: 32835259
Lancet Public Health. 2020 Oct;5(10):e536-e542
pubmed: 32950075
Intern Med J. 2020 Aug;50(8):1000-1003
pubmed: 32881225
Acta Cardiol. 2020 Jul 30;:1-7
pubmed: 32727305
Cardiovasc Revasc Med. 2021 Sep;30:33-37
pubmed: 32988743
Int J Cardiol Heart Vasc. 2020 Dec;31:100659
pubmed: 33072848
Open Heart. 2020 Oct;7(2):
pubmed: 33106441
Heart. 2020 Dec;106(23):1805-1811
pubmed: 32868280
Curr Probl Cardiol. 2021 Mar;46(3):100656
pubmed: 32839042
JACC Case Rep. 2020 Oct;2(12):2013-2015
pubmed: 32989437
Neth Heart J. 2020 Jul;28(7-8):424-430
pubmed: 32607704
JACC Case Rep. 2020 Aug;2(10):1599-1602
pubmed: 32839758
JACC Case Rep. 2020 Aug;2(10):1620-1624
pubmed: 32835261
Catheter Cardiovasc Interv. 2021 Aug 1;98(2):217-222
pubmed: 32767652
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
JACC Case Rep. 2020 Aug;2(10):1610-1613
pubmed: 32835260
Anatol J Cardiol. 2020 Oct;24(5):334-342
pubmed: 33122486
Circ Cardiovasc Qual Outcomes. 2020 Jun;13(6):e006834
pubmed: 32339038
JACC Case Rep. 2020 Aug;2(10):1637-1641
pubmed: 32839759
Clin Cardiol. 2020 Oct;43(10):1142-1149
pubmed: 32691901
J Clin Med. 2020 Jul 10;9(7):
pubmed: 32664309

Auteurs

Stéphane Rinfret (S)

Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Israth Jahan (I)

Department of Medicine and Biostatistics, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Kevin McKenzie (K)

Canadian Association of Interventional Cardiology, Ottawa, Ontario, Canada.

Nandini Dendukuri (N)

Department of Medicine and Biostatistics, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Kevin R Bainey (KR)

Division of Cardiology, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.

Samer Mansour (S)

Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Division of Cardiology, Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada.

Madhu Natarajan (M)

Division of Cardiology, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.

Luiz F Ybarra (LF)

Division of Cardiology, London Health Sciences Centre, London, Ontario, Canada.

Aun-Yeong Chong (AY)

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Simon Bérubé (S)

Division of Cardiology, CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada.

Robert Breton (R)

Division of Cardiology, CIUSSS Saguenay Lac Saint Jean, Saguenay, Quebec, Canada.

Michael J Curtis (MJ)

Division of Cardiology, Foothills Medical Centre, Calgary, Alberta, Canada.

Josep Rodés-Cabau (J)

Multidisciplinary Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Hôpital Laval, Quebec City, Quebec, Canada.

Amlani Shy Shoaib (A)

Division of Cardiology, William Osler Health System, Brampton, Ontario, Canada.

Alireza Bagherli (A)

Division of Cardiology, Windsor Regional Hospital, Windsor, Ontario, Canada.

Warren Ball (W)

Division of Cardiology, Peterborough Regional Health Centre, Peterborough, Ontario, Canada.

Alan Barolet (A)

Division of Cardiology, University Health Network-Toronto General Hospital, Toronto, Ontario, Canada.

Hussein K Beydoun (HK)

Division of Cardiology, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada.

Neil Brass (N)

Division of Cardiology, CK Hui Heart Centre/Royal Alexandra Hospital, Edmonton, Alberta, Canada.

Albert W Chan (AW)

Division of Cardiology, Royal Columbian Hospital, New Westminster, British Columbia, Canada.

Franco Colizza (F)

Division of Cardiology, Centre Hospitalier Pierre-Boucher, Longueuil, Quebec, Canada.

Christian Constance (C)

Division of Cardiology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.

Neil P Fam (NP)

Division of Cardiology, St. Michael's Hospital, Montreal, Quebec, Canada.

François Gobeil (F)

Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Tinouch Haghighat (T)

Division of Cardiology, CISSSO-Hull Hospital, Gatineau, Quebec, Canada.

Steven Hodge (S)

Division of Cardiology, Kelowna General Hospital, Kelowna, British Columbia, Canada.

Dominique Joyal (D)

Division of Cardiology, Jewish General Hospital, Montreal, Quebec, Canada.

Hahn Hoe Kim (HH)

Division of Cardiology, St-Mary's Regional Cardiac Care Centre, Kitchener-Waterloo, Ontario, Canada.

Sohrab Lutchmedial (S)

Division of Cardiology, Saint John Regional Hospital, Saint John, New Brunswick, Canada.

Andrea MacDougall (A)

Division of Cardiology, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada.

Paul Malik (P)

Division of Cardiology, Kingston General Hospital, Kingston, Ontario, Canada.

Steve Miner (S)

Division of Cardiology, Southlake Regional Health Centre, Newmarket, Ontario, Canada.

Kunal Minhas (K)

Division of Cardiology, St. Boniface General Hospital, Winnipeg, Manitoba, Canada.

Jason Orvold (J)

Division of Cardiology, Royal University Hospital, Saskatoon, Saskatchewan, Canada.

Donald Palisaitis (D)

Division of Cardiology, Sacred Heart Hospital, Montreal, Quebec, Canada.

Brendan Parfrey (B)

Division of Cardiology, Health Sciences Centre, St-John's, Newfoundland, Canada.

Jean-Michel Potvin (JM)

Division of Cardiology, CHU de Québec, Quebec City, Quebec, Canada.

Geoffrey Puley (G)

Division of Cardiology, Trillium Health Centre, Mississauga, Ontario, Canada.

Sam Radhakrishnan (S)

Division of Cardiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Marco Spaziano (M)

Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Jean-François Tanguay (JF)

Division of Cardiology, Cardiology Institute of Montreal, Montreal, Quebec, Canada.

Ram Vijayaraghaban (R)

Division of Cardiology, Rouge Valley Centenary, Scarborough, Ontario, Canada.

John G Webb (JG)

Division of Cardiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Rodney H Zimmermann (RH)

Division of Cardiology, Regina General Hospital, Regina, Saskatchewan, Canada.

David A Wood (DA)

Division of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.

James M Brophy (JM)

Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

Classifications MeSH